Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-121 safety study in healthy adults
NL-OMON59664Phase 1Completed
- Sponsor
- argenx
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ARGX-121, sponsored by argenx. Started Jun 2025; status: completed.
02
Drugs
ARGX-121
Beyond the preview
Go deeper on NL-OMON59664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59664.